Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-PPX: switching study of fitusiran prophylaxis in hemophilia A and B
2016-004087-19Phase 3Terminated
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of fitusiran in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Annualized bleeding rate (ABR). Started Jul 2017; status: terminated.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2016-004087-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004087-19.